The aim of this pilot study was to analyze the association between DNA methylation patterns in breast cancer specimens and response to trastuzumab in a cohort of 12 trastuzumab-treated, non-metastatic HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.